Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

M&A Analysis: February, Onco And Cardio Deals Invade Frosty Month

Executive Summary

Medtech Insight recorded nine newly announced deals in February, a decline from the 17 deals recorded in January 2017 and the 12 noted in the same period last year. Nevertheless, it proved to be a busy month in the oncology and cardiovascular space, with radiotherapy specialist Varian racking up two deals in the same month to expand its cancer portfolio.

You may also be interested in...



New Report Spotlights Intensifying Rivalry Between Tech And Health-Care Companies

More than 75% of Fortune 500 life-science companies may fall out of that ranking by 2023 amid rising competition from tech giants like Apple, Microsoft and Alphabet, as well as smaller tech players that offer data-driven health services and products that meet the needs of a changing value-based and consumer-driven health-care environment, according to a new Ernst & Young report.

Teijin Takes Stake In Maglev Heart Assist Device Co

As it continues to build-up its medical device business, Japanese group Teijin has acquired MedTech Heart, which is developing a maglev ventricular assist device for heart failure patients.

Roche To Improve Real-World Cancer Data Extraction With Flatiron Buy

Acquisition reflects that regulatory-grade real-world evidence will play increasing role in drug discovery, development, commercialization and reimbursement.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel